- Article
- Source: Campus Sanofi
- 18 Sep 2025
Unmet Needs
Today, all treatment options (e.g., insulin, CGMs) are used to help stage 3 patients manage blood glucose levels.1
No treatments are available to target the underlying autoimmune pathogenesis and impact the disease trajectory.2
Individuals who have family antecedents with aT1D have up to 15x higher risk of developing T1D, per consensus guidelines (ADA, BRT1D, BreakthroughT1D)
The incidence and prevalence of T1D are increasing globally3
The global prevalence of T1D will rise to 13.5–17.4 million by 20404
(60–107% rise by 2040)
Only 15% of newly diagnosed people with T1D have a family history of the disease5
15-fold higher risk of developing T1D in first-degree relative6
The risk of cardiovascular complications increases the earlier the age an individual progresses to Stage 37
The prevalence of DKA at onset of aT1D is alarmingly high8
- Nagy G, et al. World J Diabetes 2022;13:835–50; 2. Donner T, et al. J Clin Endocrinol Metab 2012;95:1405–13.
- https://www.diabetes.org.uk/our-research/about-our-research/hot-topics/immunotherapy/what-are-immunotherapies
- Mobasseri M, et al. Health Promot Perspect 2020;10:98–115
- Gregory GA, et al. Lancet Diabetes Endocrinol 2022;10:741–60
- JDRF. https://www.jdrf.org/blog/2023/03/17/who-is-at-risk-for-type-1-diabetes/#:~:text=Having%20a%20family%20history%20of,family%20members%20with%20the%20disease. (Accessed: 20 February 2024)
- Parkkola A, et al. Diabetes Care 2013;36:348–54
- Chiesa, ST. and ML Marcovecchio. Frontiers in Pediatrics 2021:696499
- Todd Alonso G, et al. Diabetes Care 2020;43:117–21.
GULF:
One JLT Building, Level 3, Jumeirah Lake Towers, PO Box 53899, Dubai, UAE .
For further medical information, please contact: For UAE ✆ 800 MEDICAL Toll-Free Number.
For all Gulf countries ✆ +971 45 50 38 63 or email: medical-information.gulf@sanofi.com.
Full prescribing information is available upon request.
To Report adverse events please call: +971 561747001 or email Gulf.Pharmacovigilance@sanofi.com
www.sanofi.com
KSA:
To report any side effect(s):
Saudi Arabia: The National Pharmacovigilance and Drug Safety Centre (NPC
SFDA call center: 19999 • E-mail: npc.drug@sfda.gov.sa • Website: https://ade.sfda.gov.sa/
Full Prescribing Information is available upon request: SANOFI, Kingdom of Saudi Arabia, P.O. Box 9874, Jeddah 21423, K.S.A.
Tel: +966-12-669-3318, Fax: +966-12-663-6191
For Medical Information, please contact: +966-12-669-3318, ksa.medicalinformation@sanofi.com
For Pharmacovigilance, please contact: +966-54-428-4797, ksa_pharmacovigilance@sanofi.com
To report any Product Technical Complaint, please contact SANOFI Quality Department:
Email: quality.greatergulf@Sanofi.com , www.sanofi.com.sa
MAT-KW-2600001-V1-Feb 2026